Business Daily Media

The Times Real Estate

.

Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

  • Written by PR Newswire
Pierre Fabre initiates a "First in Human" clinical trial for an innovative monoclonal antibody (W0180) targeting the VISTA checkpoint in patients with solid tumors

TOULOUSE, France, Nov. 9, 2020 /PRNewswire/ -- Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams. The study...

Blend AI scales up in the USA following ecommerce success

Sydney, Australia – 1st April, 2025: Blend AI, a leading Australian adtech company, has announced the opening of its first US office in Austin, Te...

Why the Way We Think About Employee Wellbeing Is Holding Us Back

Workplace wellbeing has finally reached the mainstream. It’s no longer seen as a ‘nice to have’ or an afterthought—it’s a core business issue. But d...

Samsara Eco expands global leadership team

Industry heavyweights join Samsara Eco to accelerate its enzymatic recycling technology Chief Innovation Officer and Executive Product Director a...

National Print Awards Announce Ricoh Women in Industry Award

The National Print Awards (NPAs) are proud to introduce the Ricoh Women in Industry Award, a prestigious new accolade recognising and celebrating ...

Financial Forecasting: 3 Tips for SMEs

Financial forecasting means predicting your business’s future revenue, expenses, and cash flow so you can plan ahead. If you’ve ever wondered whether ...

NextOre Unveils World First MR Analyser for Underground Copper Trucks

NextOre, a global leader in  Magnetic Resonance (MR)-enabled bulk ore sorting technology, has now made its world first sensor system available for...

Sell by LayBy